Position in CYTK
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
New position
Shares Held
0
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Derivatives in CYTK
reported options exposure · as of Mar 31, 2026CallValue
$593,190
CallShares
9,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Greenland Capital Management LP holds $9,138,618 across 8 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
14,000 | $2,621,920 | |
| 2 | ABVX |
Abivax S.A.
|
15,000 | $1,998,900 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
20,000 | $1,144,400 | |
| 4 | FDMT |
4D Molecular Therapeutics, Inc.
|
72,257 | $961,018 | |
| 5 | VRDN |
Viridian Therapeutics, Inc.\DE
|
50,000 | $918,500 | |
| 6 | MLYS |
Mineralys Therapeutics, Inc.
|
30,000 | $809,400 | |
| 7 | BHVN |
Biohaven Ltd.
|
46,000 | $684,480 | |
| 8 | TVGN |
Tevogen Inc.
|
703,029 | $0 |
All Filings in CYTK
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $593,190 | 9,000 | Call | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||